Boehringer settles Pradaxa suits

Share this article:

Boehringer Ingelheim is settling around 4,000 Pradaxa lawsuits for $650 million. The company announced Wednesday that it had reached a “comprehensive settlement of state and federal cases” and that the decision “enables Boehringer Ingelheim to focus solely on its mission of improving patients' lives.”

Bloomberg reports this breaks down to around $162,500 per suit and that the agreement comes just months before the first of several lawsuits were expected to begin in September.

The lawsuits center around claims that there was no antidote to prevent bleeding-related deaths among those who took the blood thinner.

BI announced earlier this month that it was going to start testing the antidote idarucizumab among Pradaxa patients.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.